FDA orphan drug designation for Genea Biocells’ FSHD drug candidate
[…] Administration (FDA) for its therapeutic candidate, GBC0905, for the treatment of facioscapulohumeral muscular dystrophy ( FSHD). Scientists from Genea Biocells will be attending the FSH Society’s International Research Conference and […]